Guiding Principles of the Paul-Ehrlich-Institut
We use our knowledge and expertise to ensure the quality, efficacy, and safety of biomedicines as well as their availability and the development of new products of this type of medicines.
The Paul-Ehrlich-Institut has been playing a major role in controlling the efficacy and safety of biomedicines ever since the early days of their use in the treatment and prevention of diseases more than a hundred years ago – at first, under a different name, with the Nobel prize winner, Paul-Ehrlich as its head. Since then, a wealth of experience has been gained on the successes but also the risks of using such medicines which can rarely be found world-wide. It is this basis which enables us, the staff of the Paul-Ehrlich-Institut to fulfil our must important task: We use our knowledge and expertise in the field of biologicals to serve the health of humans and animals. Even though marketing authorisations and official batch testing are essential they are not the only spheres of responsibility which have been assigned to us by statutory regulations. We are committed to the development of innovative medicines by performing research and providing our advice.
We are committed at a national, European and global level.
A mandate in the service of health is global, since health hazards do not stop at national boundaries. Fulfilling this mandate is made easier by European harmonisation and the globalisation of many other international relationships. For that reason, we provide our input through our knowledge and expertise, not only nationally but also in Europe and globally. We actively co-operate in the development of international standards with the objective of increasing the safety of drugs.
Experimental research at a high level is the indispensable basis for our competence.
Outstanding and scientifically founded expertise in all our fields of activity is an essential prerequisite for the quality and acceptance of our decisions and recommendations. We achieve this expertise by means of experimental research that is able to compete internationally. Our fields of research cover a wide area ranging from application-related issues to investigations of fundamental bio-medicinal phenomena. In this context, the development of experimental methods as an alternative to animal experiments is of particular importance.
Our work is characterised by high quality combined with short processing times and cost-effectiveness.
Only a consistently high quality of our work can ensure that our commitment to the safety and efficacy of biological drugs produces results. In this respect, the legitimate interests of the pharmaceutical manufacturers and the ever scarcer availability of resources must also be taken into account. Therefore, the demands on the quality of our work are combined with a result-oriented approach and cost-effectiveness.
We are ready to face up to international competition.
The European rules governing the marketing of medicinal products have opened up new possibilities for the manufacturers of pharmaceuticals. While in the past, they had to apply to the competent authority of their own country, they now have the option of selecting a competent authority in any of the EU member states for a Europe-wide centralised procedure for a number of products. This is creating competition among the authorities of the European Union member states, a challenge which is being successfully met by the staff members of the Paul-Ehrlich-Institut. Over the next few years, our plan is to be chosen even more often by the pharmaceutical manufacturers as their competent partner.
Initiative, commitment and teamwork are instrumental in achieving our objectives.
The challenge we have accepted is complex and can hardly be mastered by individuals alone. Our objective can be achieved only by jointly agreed action combined with specialist knowledge. This also means that the skills of staff members should be improved by a number of measures including further training, and that they should be encouraged in their readiness to assume responsibility. Everyone should have the same opportunities to develop abilities to his or her full potential. Not only the purpose and objective of our work, but also the way in which it is implemented, encourage us to perform our tasks with special commitment.
Our work is characterised by impartiality and confidentiality, wherever necessary, and transparency, wherever possible.
In realising our tasks and objectives we maintain the highest degree of honesty, impartiality and, as far as necessary, confidentiality vis-à-vis vaccinated persons, patients, users and manufacturers. We are enhancing the transparency of our work in an effort to provide better information to the general public, the members of the medicinal professions and the pharmaceutical industry.